Jun 19, 2020   SOURCE: PR NewsWire

Biomarker Technologies Market Size Hit US$ 117,853 Mn By 2027

LOS ANGELES, June 19, 2020 /PRNewswire/ -- Acumen Research and Consulting, Recently Published Report on "Biomarker Technologies Market Size, Share, Growth, Trends, Revenue and Forecast, 2020-2027".

https://mma.prnewswire.com/media/962993/Acumen_Research_and_Consulting_Logo.jpg

Biomarker technology is for the rational development of medical therapeutics. The applications include diagnostic, monitoring, pharmacodynamic/response, predictive, prognostic, safety, and susceptibility/risk biomarkers. It has major uses in research and clinical practice, particularly in the fields of chronic disease and nutrition. The biomarker technology market is particularly gaining growth on account of increasing healthcare facilities in developing economies. Increasing geriatric population, R&D funding, technological advancement, and increasing cases of geriatric population are some of the factors accelerating the market growth.

Get Free Report Sample Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1945

The biomarker technologies market is segmented into test type, product, technology, application, indication, and major geographic regions. On the basis of test type, market segments include solid biopsy and liquid biopsy. By product, the market is divided into consumables, instruments, services, and software/informatics. Based on technology, the market bifurcated into ddPCR, NGS, immunoassay, mass spectrometry, DHPLC, other technologies. Additionally, it has found applications across drug discovery, diagnostics, and personalized medicine. By indication, the market is bifurcated into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others.

By product, the consumables segment accounted for the maximum share in 2019. The segment is also projected to continue at the same pace over the forecast period from 2020 to 2027. The consumables include reagents & kits and chromatography columns and are getting maximum share due to their large sales volume.

In 2019, North America held the major share of the global biomarker technologies market. The region is further projected to continue with its dominance over the estimated timeframe. The well-established healthcare infrastructure and favorable reimbursement scenario are favoring the regional market value. The rising prevalence of diseases such as cancer, autoimmune diseases, cardiovascular diseases & neurological diseases, increasing expenditure on health, and rising geriatric population are other factors supporting the market value. Apart from these, Asia Pacific region is projected to experience the fastest growth over the estimated period from 2020 to 2027.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/biomarker-technologies-market

Some of the leading competitors are Agilent Technologies (US), Bio-Rad Laboratories (US), Danaher Corporation (US), F. Hoffmann-La Roche AG, Illumina, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Roche (Switzerland), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), and Waters Corporation (US). Biomarker technologies companies have announced mergers and acquisitions to expand their position in the biomarker technologies industry. Major players are also moving into new regions and advanced technologies for market expansion.

Some of the key observations regarding biomarker technologies industry include:

    --  Australian start-up, Nutromics is developing painless "The world-first
        personalized nutrition wearable" that measures key dietary biomarkers
        and sends the information to an app, enabling users to precisely track
        how their bodies respond to different foods. The wearable smart patch is
        intended to deliver precision data to help people personalize their
        diets and reduce their risk of developing lifestyle-related chronic
        diseases like Type 2 diabetes.
    --  Medicortex Finland Oy, a biopharmaceutical company is developing
        diagnostics and drug treatment for mild traumatic brain injury (TBI) in
        2020. The company has announced that it has received European Patent No.
        3283880 for "Prognostic and diagnostic glycan-based biomarkers of brain
        damage" from the European Patent Office (EPO) in 2020. The kit comprises
        specific biomarkers that the company has discovered from body fluids
        following brain injury.
    --  Researchers from Graz have now developed a test for early detection of
        sepsis. Researchers have discovered biomarkers that are useful for
        detecting blood poisoning at an early stage and according to the early
        detection can increase the chance of survival for a significant number
        of patients because as per statistics every year 8% of all deaths in
        Austria are caused by blood poisoning. The team has identified 24
        biomarkers that are capable of detecting sepsis at an earlier stage than
        what was previously possible.
    --  The researchers from The University of Texas MD Anderson Cancer Center's
        Therapeutics Discovery division and Ipsen Biopharmaceuticals reported
        the preclinical discovery and early-stage clinical development of a
        novel drug, IPN60090. The new drug is under investigation in a Phase I
        trial and expected to hold benefits for certain patients with lung and
        ovarian cancers. Furthermore, the analysis revealed biomarkers of
        response, which have been leveraged to identify patients most likely to
        benefit.

Browse More Healthcare Industry Research Reports, Click here@ https://www.acumenresearchandconsulting.com/industry-categories/healthcare-and-pharmaceuticals

Market Segmentation

Market By Test Type

    --  Solid Biopsy
    --  Liquid Biopsy

Market By Product

    --  Consumables
    --  Instruments
    --  Services
    --  Software/Informatics

Market By Technology

    --  ddPCR
    --  NGS
    --  Immunoassay
    --  Mass Spectrometry
    --  DHPLC
    --  Other Technologies

Market By Application

    --  Drug Discovery
    --  Diagnostics
    --  Personalized Medicine

Market By Indication

    --  Cancer
    --  Infectious Diseases
    --  Autoimmune Disorders
    --  Cardiovascular Disorders
    --  Others

Market By Geography

North America

    --  U.S.
    --  Canada

Europe

    --  UK.
    --  Germany
    --  France
    --  Spain
    --  Rest of Europe

Asia-Pacific

    --  China
    --  Japan
    --  India
    --  Australia
    --  South Korea
    --  Rest of Asia-Pacific

Latin America

    --  Brazil
    --  Mexico
    --  Rest of Latin America

Middle East & Africa

    --  GCC
    --  South Africa
    --  Rest of Middle East & Africa

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1945

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1945

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: sales@acumenresearchandconsulting.com
Website: https://www.acumenresearchandconsulting.com

View original content:http://www.prnewswire.com/news-releases/biomarker-technologies-market-size-hit-us-117-853-mn-by-2027--301080314.html

SOURCE Acumen Research and Consulting